Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.

KCNQ2 downregulation in left stellate ganglion neurons exacerbates malignant ventricular arrhythmias after myocardial infarction.

FFR-Guided Complete versus Culprit-Only Revascularization in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis.

PRMT1 promotes H2O2 induced cardiomyocytes cell via mediating arginine methylation of P53.

Myocardial infarction (MI), a global health crisis driven by dysregulated immune responses and genetic-environmental interplay, remains inadequately addressed by current therapies targeting programmed cell death (PCD). While apoptosis, mitophagy, and pyroptosis collectively orchestrate MI progression. Emerging evidence underscores the pivotal roles of mitophagy and pyroptosis in regulating NLRP3 inflammasome activation, however, the crosstalk between these processes remains a critical unresolved question in cardiovascular immunology. Here, we identify Triggering Receptor Expressed on Myeloid cells 1 (TREM1) as a central molecular nexus governing this axis. Leveraging integrative bioinformatics analysis of the GSE66360 dataset combined with functional validation in macrophage-specific and MI rodent models, we demonstrate that TREM1 overexpression suppresses PINK1/Parkin-mediated mitophagy while paradoxically exacerbating NLRP3-dependent pyroptosis. Moreover, TREM1 knockdown significantly improved post-MI cardiac function and attenuated fibrotic remodeling. These findings establish TREM1 as both a prognostic biomarker for MI and a pleiotropic therapeutic target capable of simultaneously dampening NLRP3 inflammasome hyperactivation and promoting cardiac functional recovery.

A coordinated biomaterial strategy for post-infarction cardiac repair: integrating tailored mechanical reinforcement with hiPSC-derived cardiomyocytes in composite engineered human myocardium for remuscularization.

Previous evidence on the associations of dairy intake with risk of cardiometabolic diseases has been inconsistent with studies showing inverse, null, or positive associations. We aimed to assess these associations in China, where dairy consumption level is low and cardiometabolic disease patterns differ from those in the West. The China Kadoorie Biobank is a prospective cohort study with ∼512,000 adult participants recruited from 10 diverse localities in China during 2004-2008. At baseline and periodic resurveys, information on the consumption frequency of major food groups was collected using a validated interviewer-administered laptop-based questionnaire. During ∼ 5.4 million person-years of follow-up, 18,306 diabetes, 33,946 ischemic heart diseases [IHD, including 3888 acute myocardial infarction (MI)], 33,670 ischemic stroke, 7191 intracerebral hemorrhage (ICH) cases, and 13,241 cardiovascular deaths were recorded. Cox regression was used to calculate adjusted hazard ratios (HRs) relating dairy intake to cardiometabolic disease risk. At baseline, 10.7% of participants regularly consumed (i.e., ≥4 d/wk) dairy products, whereas 70.0% reported never or rare consumption. After adjusting for potential confounders including body mass index, dairy consumption was significantly and positively associated with IHD but inversely associated with risks of acute MI, ICH and cardiovascular death, with HRs for regular consumers compared with nonconsumers being 1.09 (95% CI: 1.06, 1.12), 0.88 (0.80, 0.98), 0.69 (0.62, 0.76), and 0.82 (0.77, 0.87), respectively, but not with diabetes and IS. These associations were largely independent of systolic blood pressure. In Chinese adults, higher dairy consumption was associated with lower risks of acute MI, ICH, and cardiovascular death. Future studies are warranted to further elucidate these relationships and their causality.

Introduction: Hypertensive emergencies represent lifethreatening conditions characterised by acute elevations in blood pressure with evidence of target organ damage. They remain a significant contributor to cardiovascular, neurological, and renal morbidity and mortality, often leading to hospitalisation. Early detection of end-organ involvement is therefore crucial to prevent irreversible damage and improve clinical outcomes. Aim: To study the association between patients presenting with hypertensive emergency in the Medical Intensive Care Unit (MICU) and target end-organ damage across different genders and age groups. Materials and Methods: The present cross-sectional study was conducted among adult patients aged 18-80 years presenting with blood pressure ≥180/120 mmHg at R. D. Gardi Medical College and Charitable Hospital, Ujjain, Madhya Pradesh, India, over a period of six months, from June 2024 to November 2024. Demographic data, medical history, and other clinical information, including Electrocardiography (ECG), Two Dimensional (2D) echocardiography, chest X-ray, funduscopic examination, ultrasonography of the abdomen, and neuroimaging studies, were collected. Data were analysed using SPSS software (Statistical Package for the Social Sciences (SPSS) Inc., Chicago, IL), version 29.0.10, with a p-value <0.05 considered statistically significant. Results: Among the 96 patients, 58 (60%) were male and 38 (40%) were female. The mean {±Standard Deviation (SD)} age was 58.66±12.62 years (range: 18-80 years). A past history of hypertension was present in 58 (60.4%) patients, with a mean duration of 6.51±4.34 years (range: 1-20 years). The most common forms of acute target organ damage were Cerebrovascular Accident (CVA) with retinopathy in 24 patients (25%), followed by Myocardial Infarction (MI) with retinopathy in 15 (15.6%), retinopathy alone in 13 (13.5%), retinopathy with pulmonary oedema and acute heart failure in 11 (11.5%), and MI alone in 10 patients (10.4%). Conclusion: Hypertensive emergencies were more frequent among middle-aged and elderly males, most of whom had a prior history of hypertension. CVAs and retinopathy were the leading complications, followed by MI either alone or in combination with retinopathy. Strengthening early detection and ensuring strict blood pressure control are essential to reduce the burden of target organ damage in these patients.

Myocardial infarction (MI), a leading cause of heart failure, involves dynamic pathological progression from acute ischemia to maladaptive fibrosis. To address this complexity, we engineered an injectable alginate composite hydrogel enabling spatiotemporal codelivery of dual therapeutics targeting distinct MI phases. The system incorporates: (i) UCL-TRO-1938, a newly identified PI3Kα activator promoting angiogenesis via PI3K/Akt signaling, released immediately during the acute injury phase; and (ii) engineered mesoporous silica nanoparticles encapsulating bone morphogenetic protein-9 (BMP-9); these nanoparticles feature an epigallocatechin gallate/zinc ion complex coating enabling pH-responsive payload release specifically within acidic infarct microenvironments. This design aims to align the release of UCL-TRO-1938 with the early demands of angiogenesis and delay BMP-9 release to coincide with the later phase of fibrosis progression. Comparative studies in murine myocardial infarction models showed that this dual-delivery platform resulted in improved outcomes compared with single-agent therapies. Intramyocardial administration significantly reduced apoptosis, enhanced angiogenesis, attenuated fibrosis, and improved cardiac function relative to controls. By synchronizing material properties with stage-specific biological responses, this temporally programmed strategy, which aligns with the pathological progression of MI, achieves enhanced functional recovery compared to conventional monotherapies, providing a clinically viable approach for myocardial repair.

Balancing ischemic versus bleeding complications following percutaneous coronary intervention (PCI) remains challenging. However, the optimal dose of unfractionated heparin (UFH) for elective PCI is currently unclear. A Randomized Trial of Higher versus Lower Dose Heparin for PCI (HD-PCI) is a multicenter, randomized, controlled, registry-based, open-label, cluster crossover trial of a lower-dose (70 units/kg) versus higher-dose (100 units/kg) UFH dosing hospital-level policy for elective PCI conducted in 11 centres in Ontario, Canada. The primary efficacy outcome was defined as a composite of all-cause death, myocardial infarction or target vessel revascularization; the key safety outcome was defined as major bleeding; and the key net benefit outcome was defined as the composite of all-cause death, myocardial infarction, target vessel revascularization or major bleeding. All outcomes were evaluated within 30 days of the index PCI. HD-PCI is a large cluster randomized crossover trial that will inform the ischemic and bleeding effects of lower-dose (70 units/kg) versus higher-dose (100 units/kg) in patients undergoing elective PCI. ClinicalTrials.gov Identifier NCT04049591.

Liver fibrosis scores predict cardiovascular outcomes in myocardial infarction and non-obstructive coronary arteries patients with and without diabetes or prediabetes.

NMR-based metabolic measures of chronic stable angina and myocardial infarction in patients with diabetes mellitus.

Natural polysaccharide-nucleic acid nanocomplex alleviates myocardial infarction by driving chronologically programmed macrophage polarization.

Geometric deep learning-based coronary wall shear stress estimation from real-world patients.

External validation and recalibration of cardiovascular risk scores for prediction of 10-year risk of fatal cardiovascular disease: a prospective, observational, population-based cohort analysis of adults in Mexico City.

Association of body mass index and length of stay in patients undergoing minimally invasive surgery for uterine cancer: a National Surgical Quality Improvement Program (NSQIP) study.

High-intensity versus very-high-intensity statin, both on top of ezetimibe, in acute myocardial infarction: A pragmatic randomized study.

Percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) did not improve left ventricular systolic function. The left atrioventricular coupling index (LACI), derived from cardiovascular magnetic resonance (CMR), reflects diastolic atrioventricular coupling and has recently emerged as a parameter for diastolic dysfunction and a prognostic marker after acute myocardial infarction. We aimed to assess the impact of CTO PCI on LACI in patients with ST-elevation myocardial infarction (STEMI) and concurrent CTO METHODS: In this CMR substudy of the multicentre randomised controlled EXPLORE trial, 200 patients (mean age 60±10years, 88% male) underwent baseline CMR, and 178 patients had analysable 4-month follow-up CMR. LACI was defined as the ratio of left atrial and left ventricular end-diastolic volumes. The primary outcome was the effect of CTO PCI on LACI and change of LACI over time RESULTS: The significant improvement in LACI over time (Δ LACI - 1.0% [Q1-Q3: - 4.6 to 2.0], P=0.005) was independent of CTO PCI or no-CTO PCI (P=0.706). CTO PCI did not influence the change in LACI (- 0.8% [Q1-Q3: - 4.7 to 2.2], P=0.122). Baseline LACI ≥20.6% was associated with an increased risk of all-cause death compared to LACI <20.6% after multivariable adjustment (hazard ratio 2.37, 95% CI: 1.27 to 4.45, P=0.007) CONCLUSIONS: Among STEMI patients with a concurrent CTO, CTO PCI did not affect LACI at 4months or its improvement over time. Elevated LACI early after STEMI independently predicted long-term all-cause mortality Clinical trial registration: The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) trial; NTR1108 www.trialregister.nl, Date registered NTR: 30-okt-2007.

In this study, we assessed the association of modern systemic hormonal contraception (HC), including newly introduced estradiol-containing combined oral contraceptives, with major adverse cardiovascular events (MACE): myocardial infarction [MI] and ischemic stroke [IS], during 2018-2019. A prospective registry-based cohort study including all 15-49-year-old women residing in Finland in 2017, using HC. We identified women from the national prescription register and incident cases of MACE from the national patient register, yielding 584,236 women and 1167,685 person-years. We analysed cases and their 1:4 age-matched controls in a nested case-control design assessing the association between use vs. non-use of different HC and risk of MACE. Altogether 19.1% of women used combined hormonal contraceptives (CHC), 8.0% ethinylestradiol (EE) and 3.7% estradiol (E2) containing pills while 7.5% used progestin-only-pills (POP). We recorded altogether 334 cases of MACE (84 MI and 250 IS), with an incidence rate of 28.6/100,000 person-years (7.2/100,000 for MI and 21.4/100,000 for IS). Compared to non-use of HC, the adjusted odds ratios (95% CI) of MACE were 1.24 (0.78 - 1.96) and 1.37 (0.73- 2.57) among users of EE and E2 containing HC, and 1.04 (0.64 -1.71) among users of POP. We found no increased risk of MACE associated with use of CHCs containing either EE or E2, or with POP, compared to non-use. We speculate that the cardiovascular safety of modern use of HC is linked both to improved safety of modern contraceptives and their appropriate use. The present findings are reassuring concerning the cardiovascular safety of modern HC, suggesting that use of modern hormonal contraceptives, when aligned with current guidelines, does not significantly increase the risk of MACE.

We report our initial cases of robotic left atrial appendage occlusion (LAAO) device deployment. From June 2021 to December 2024, all consecutive patients undergoing robotic-assisted LAAO (isolated or with robotic-assisted CABG) using an epicardial clip were enroled. The study protocol was approved by the Institutional Review Board (IRB 45CFR164.512). A total of 28 patients were included, 22 of which underwent a concomitant CABG. Transesophageal echocardiogram confirmed excellent exclusion of the LA appendage in all but one patient. There were no postoperative strokes, myocardial infarctions, reoperation for bleeding, unplanned revascularisation, or deaths. At a median of 1.4 [0.9-1.8] years, there was 1 non-cardiac mortality (cancer) and 1 stroke. Nine (32.1%) patients were off OAC, while 21 (75.0%) were off class I-III antiarrhythmic drugs. These early results show optimal stroke prevention outcomes, considering the high-risk level of the patients. Longer follow-up is warranted to confirm these outcomes.